SEATTLE, WA--(MARKET WIRE)--Jun 28, 2007 -- Targeted Genetics Corporation (NasdaqCM:TGEN - News) today announced the completion of its private equity offering of 6.7 million shares of its common stock at a purchase price of $2.905 per share, together with warrants to purchase up to an aggregate of 6.7 million shares of common stock, subject to adjustment pursuant to the terms of the warrants, at a price of $3.25 per share of common stock. The gross proceeds from this financing were $19.5 million, with net proceeds from the financing of approximately $17.8 million after deducting the estimated costs associated with the transaction.
